NUTENT THERAPEUTICS, INC.
2800 E SUNRISE BLVD., UNIT 1, FLORIDA

Nutent Therapeutics, Inc. is a pioneering company in the nutraceutical industry, founded on integrating clinical trials to support product claims—a novel approach that distinguishes its portfolio both domestically and internationally. Established as a C-corporation under Delaware law in January 2017, Nutent operates from Boca Raton, Florida. The firm emerged from a strategic spin-off of Levolta Pharmaceuticals, Inc., with core leadership composed of Richard P. Becker Jr (CEO), Ketan Desai (CMO) and Renee Stewart (CSO), who embody both its foundational vision and ownership. Prior to generating revenue, Nutent's anticipated commercial launch in Q2 2018 involved VOLT03, a product in-licensed from Levolta Pharmaceuticals. The initiative to reinvest first revenues into reaching critical business milestones underscores the company's aggressive development strategy. Nutent Therapeutics sets itself apart by promoting products backed by clinical data, facilitating market acceptance with substantiated health benefits underpinned by extensive research. This commitment extends to securing approval in international markets where such evidence is mandatory. The company's CEO, Richard P. Becker Jr., leverages over two decades of expertise across major pharmaceutical enterprises to propel Nutent’s growth. His substantial track record includes the successful commercialization of multiple products and strategic leadership roles at industry giants like BASF, Bayer, and Novartis. Nutent is poised to advance its portfolio by commercializing high-quality pharmaceutical-grade nutraceuticals that have been rigorously validated through clinical trials spanning various therapeutic categories. This robust approach positions the company as a forerunner in leveraging scientific research to enhance product credibility and market potential.